Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Intentional mixture of two or more micro-organisms – cells,...
Reexamination Certificate
2007-06-12
2007-06-12
Zeman, Robert A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Intentional mixture of two or more micro-organisms, cells,...
C424S093100, C424S093400, C424S093450, C424S184100
Reexamination Certificate
active
11111255
ABSTRACT:
The present invention relates to the use of a supernatant of lactic acid bacteria or of Bifidobacteria capable of preventing colonization of intestinal cells byGiardia intestinalis, for the preparation of an ingestible carrier for the treatment and/or prophylaxis of disorders associated with the colonization of the gut byGiardia intestinalis. The present invention also pertains to specific strains of Bifidobacterium having the above traits and to the ingestible carrier, such as a food or pharmaceutical composition, containing such supernatant or the microorganisms.
REFERENCES:
patent: 5603930 (1997-02-01), Brassart et al.
patent: 5902578 (1999-05-01), Halpin-Dohnalek et al.
patent: 6521443 (2003-02-01), Zink et al.
patent: 2005/0186191 (2005-08-01), Schiffrin et al.
patent: 0577904 (1994-01-01), None
patent: WO 97/35596 (1997-10-01), None
patent: WO9735596 (1997-10-01), None
patent: WO0130365 (2001-05-01), None
patent: WO9629083 (2006-11-01), None
Chavez et al., “Giardia iamblia; In Vitro Cytopathic Effect on Human Isolates,” Experimental Parasitology 80, 1995, pp. 133-138.
Buret et al., “Pathophysiolgy of Small Intestinal Malabsorption in Gerbils Infected WithGiardia iamblia,” Gastroenterology 103, 1992, pp. 506-513.
Roberts-Thompson, et al., “Giardiasis in the Mouse: An Animal Model,” Gastroenterology 71, 1976, pp. 57-61.
Aley et al., “Specialized Surface Adaptations ofGiardia iamblia” Infectious Agents and Disease, 4, 1995, pp. 161-166.
Muller et al., “Serological Analysis of Antigenic Heterogeneity ofGiardia iambliaVariant Surface Proteins,” Infection and Immunity, 64, 1996, pp. 1385-1390.
Nash et al., “Giardia iamblia: Identification and Characterization of a Variant-Specific Surface Protein Gene Family”, J. Euk. Microbiol., 42, 1995, pp. 604-609.
Gillin et al., “Cell Biology of the Primitive EukaryoteGiardia lamblia,” Annu. Rev. Microbiol, 50, 1996, pp. 679-705.
Katelaris et al., “Activity of Metronidazole, Azithromycin and Three Benzimidazoles onGiardia lambliaGrowth and Attachment to a Human Intestinal Cell Line,” Altment Pharmacol. Ther. 8, 1994, pp. 187-192.
Thompson et al., “Nomenclature and Genetic Groupings ofGiardiaInfecting Mammals,” Parasitology Today, vol. 16, No. 5, 2000, pp. 210-213.
Reiner et al., “Human Milk KillsGiardia lambliaby Generating Toxic Lipolytic Products,” The Journal of Infectious Diseases, vol. 154, No. 5, 1986, pp. 832-835.
Perez Pablo
Schiffrin Eduardo
Bell Boyd & Lloyd LLP
Nestec S.A.
Tongue Lakia J.
Zeman Robert A.
LandOfFree
Lactic acid bacteria for the treatment and/or prophylaxis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactic acid bacteria for the treatment and/or prophylaxis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactic acid bacteria for the treatment and/or prophylaxis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3868487